-
The Biggest Myths About Placebo Groups in Clinical Trials
The placebo group is the most misunderstood element of clinical trial design. It is the feature that most frequently causes people to dismiss trial participation as potentially pointless, to assume they might be receiving no treatment at all, and to conclude that the risk of joining a trial outweighs the benefit if there is a…
-
What It Actually Feels Like to Be in a Clinical Trial: A Patient’s Account
The public understanding of clinical trials is shaped almost entirely by two sources: news coverage of trial results, which focuses on outcomes and statistics, and the informed consent documents that participants receive before enrolling, which focus on procedures and risks. Neither source addresses the lived experience of participation, the texture of what it is actually…
-
Phase 4 Clinical Trials: What Happens After a Drug Gets Approved
The moment a drug receives regulatory approval is widely understood as the end of the clinical trial process. The research is done, the evidence has been reviewed, the regulator has said yes, and the medication moves from the controlled environment of a trial into the hands of prescribing physicians and their patients. That understanding is…
-
How Clinical Trial Data Becomes a Treatment Your Doctor Can Prescribe
The gap between the moment a clinical trial produces a positive result and the moment a patient can receive the treatment that result supports is one of the least understood and most consequential processes in medicine. It typically takes between one and three years from the completion of a pivotal Phase 3 trial to regulatory…